VSVioletta A Shorokhova

Violetta A Shorokhova

*This is an algorithmically generated author record based on publicly available information.

Violetta A Shorokhova has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of the efficacy, safety, and cost-effectiveness of clofazimine in the treatment of drug-resistant tuberculosis: a systematic review

    by Alexey M. Tikhonov, Sergey A. Pavlov, Andrey V. Zakharov, Violetta A Shorokhova, Valentina V Algazina, Vladimir V. Romanov

    Currently, new chemotherapy regimens for drug-resistant tuberculosis are being actively introduced into phthisiat-ric practice around the world, using new and promising chemotherapy drugs. Objective: to evaluate the efficacy, safety, and economic feasibility of clofazimine in the treat-ment of drug-resistant tuberculosis based on data from randomized clinical trials, cohort studies, and observation-al studies. Methods. In preparation for the publication, a search was conducted in the PubMed, Web of Science, and EMBASE databases for studies published before Ja-nuary 1, 2025. An analysis was conducted of published randomized controlled trials, cohort studies, and obser-vational studies comparing treatment regimens for multi-drug-resistant TB with and without clofazimine, as well as regimens with other drugs (bedaquiline, linezolid, and delamanid). The study evaluated the efficacy (sputum cul-ture conversion, treatment success), safety (frequency and types of adverse events), and economic feasibility (drug costs, treatment duration, and indirect costs). Results. Clofazimine shows significant efficacy in TB treatment regimens with various types of drug resistance, not limited to MDR TB, but also demonstrating potential for XDR TB. The drug significantly accelerates the conversion of spu-tum culture and increases the success rates of treatment. Clofazimine is generally well-tolerated in the treatment of drug resistance ТB, but its use is associated with specific, manageable adverse events (AE). The most common AE are skin discoloration (up to 94.3% of patients) and ichthy-osis (47.2%). Clofazimine-based regimens have significant cost-effectiveness due to reduced treatment duration and improved resource utilization in low-income settings. Studi-es show that clofazimine-containing regimens can reduce the treatment duration for MDR TB from 18–24 months to 9 months, which reduces healthcare costs and patient burden. Conclusion. Clofazimine demonstrates significant efficacy, safety, and cost-effectiveness in the treatment of drug-resistant TB, especially in resource-constrained set-tings. It has a predictable safety profile, but requires ECG monitoring when co-prescribed with other QT-prolonging drugs. Its use is cost-effective as part of a strategy to imple-ment shorter treatment regimens.

  • Open Access

    The effectiveness and safety of complex treatment of patients with drug-resistant pulmonary tuberculosis using delamanide

    by A. M. Tikhonov, R. V. Tarasov, A. S. Polyakova, M. N. Kovalevskaya, V. A. Shorokhova, P. D. Merzlikina

    Background. In 2020, a new anti-tuberculosis drug, delamanid, was first approved and introduced in Russia for the treatment of drug-resistant TB (DR), and therefore it is interesting to study its effectiveness and safety.The aim. To evaluate the efficacy and safety of delamanid-containing chemotherapy regimens in patients with multidrug-resistant tuberculosis as part of complex treatment compared with standard regimens.Methods. A bidirectional cohort study was conducted, including 76 patients with pulmonary tuberculosis with DR TB, divided into two comparable groups. Group 1 included 38 patients in thechemotherapyregimenwhoweretreatedwithdelamanide, the group was recruited prospectively. Group 2 included 38 patients who used chemotherapy regimens without the inclusion of delamanide, the group was recruited retrospectively.Results. The effectiveness of treatment of patients with DR TB pulmonary tuberculosis according to the criterion of cessation of bacterial excretion was 27 (79,4 %) people in group 1 against 19 people (51,4 %) in group 2 (p = 6,115, χ2 = 0,024), according to the criterion of elimination of cavities 23 patients (71,9 %) cases against 15 patients (45,5 %), respectively (p = 4,670, χ2 = 0,044). In group 1 of patients, surgical treatment was performed in the early stages of therapy by 2 months – in 9 patients (28,1 %) cases against 3 people (10,3 %) – in group 2, by 4 months – in 12 patients (37,5 %) cases against 5 patients (17,2 %), respectively. There was no statistically significant difference in adverse event frequency between the groups (p > 0,05)Conclusion. The timely use of surgical methods in patients with DR TB of the lungs, combined with the presence of delamanide in the chemotherapy regimen, made it possible to achieve higher treatment effectiveness.

  • Open Access

    Changes in Hemostasis and Fibrinolysis Rates in the Course of Treatment of New Patients with Pulmonary Tuberculosis after COVID-19 Infection

    by R. Yu. Abdullaev, V. A. Shorokhova, O. G. Komissarova

    The objective: to compare changes in markers of hemostasis and fibrinolysis during the course of treatment in new patients with pulmonary tuberculosis (TB), who suffered from COVID-19 and no COVID-19.Subjects and Methods. 50 new patients with pulmonary tuberculosis were enrolled in a retrospective study, of them 25 new pulmonary tuberculosis patients had a history COVID-19 (TB/COVID-19 Group) and 25 new pulmonary tuberculosis patients had no COVID-19 (TB Group). The state of hemostasis and fibrinolysis was assessed at four checkpoints: at admission to hospital for treatment and after 1, 2, 3 months of tuberculosis treatment. To assess the relationship between the detected changes and systemic inflammation, C-reactive protein (CRP) was additionally tested.Results. It was found that new pulmonary tuberculosis in both groups was associated with hypercoagulative shift in the hemostasis system. The incidence of patients with hypercoagulable shift decreased during the course of tuberculosis treatment in both groups. At the same time, the hypercoagulable shift leveled off significantly slower in TB/COVID-19 Group versus TB Group. Inflammatory response persisted in TB/COVID-19 Group throughout the follow-up.Conclusion. A hypercoagulability shift persisted in new pulmonary tuberculosis patients who had suffered from COVID-19 before and during tuberculosis treatment. This factor requires monitoring of hemostasis and fibrinolysis systems in such patients and, if necessary, pharmacological therapy should be used.


  • Open Access

    A Unique Case of Cure of the Patient with Disseminated Bilateral Fibrous Cavernous Pulmonary Tuberculosis with Extensive Drug Resistance after 18 Years of Treatment Failures

    by O. G. Komissarova, A. M. Tikhonov, V. A. Shorokhova, O. V. Lovacheva, N. A. Chernykh, R. Yu. Abdullaev

    The article describes a unique clinical case of 18-year comprehensive treatment of the patient with disseminated fibrous cavernous pulmonary tuberculosis with extensive drug resistance, continuous bacterial excretion and severe concomitant pathology resulting in successful cure of tuberculosis. It demonstrates the complexity of the decision-making on patient management tactics as well as a rare example of exceptional patient adherence to treatment.

  • Open Access

    Levels of markers of coagulation and fibrinolysis systems in patients with pulmonary tuberculosis with concomitant diabetes mellitus after COVID-19

    by R. Yu. Abdullaev, O. G. Komissarova, V. A. Shorokhova

    Background. It is known that COVID-19 can be followed by a shift in the hemostatic system towards hypercoagulation, which is more pronounced in the presence of diabetes mellitus (DM). Tuberculosis process is often accompanied with hypercoagulation syndrome. Of great interest is the study of the state of hemostatic systems in patients with pulmonary tuberculosis (TB) with concomitant DM who have had COVID-19.The aim. To study the relationship between the state of the hemostatic and fibrinolysis systems and moderate and severe COVID-19 in patients with pulmonary tuberculosis and diabetes mellitus.Methods. 32 patients with TB and DM were divided into two groups. Group 1 included 16 patients with TB and DM who have previously had COVID-19 (TB-DM-COVID). Group 2 included 16 patients with TB and DM who did not have COVID-19 (TB-DM).Results. It was found that TB-DM-COVID patients were more likely to develop a hypercoagulable shift compared to TB-DM patients. This was evidenced by a more frequent shortening of such indicator as activated partial thromboplastin time (43.7 % and 25.0 % of cases, respectively; χ2 = 7.22; p = 0.01), an increase in fibrinogen levels (43.7 % and 25.0%, respectively; χ2 = 7.22; p = 0.01) and D-dimer (43.7 % and 18.7 %, respectively; χ2 = 14.74; p = 0.0001). These changes were closely associated with the systemic inflammatory response, as strong and positive correlations were found between fibrinogen and C-reactive protein levels (r = 0.420; p = 0.01), and erythrocyte sedimentation rate (r = 0.433; p = 0.01) in TB-DM-COVID patients.Conclusion. In patients with pulmonary tuberculosis and diabetes mellitus after moderate and severe COVID-19, compared to patients who have not had COV ID-19, a hypercoagulable shift associated with the development of more pronounced systemic inflammation develops more often.

  • Open Access

    Indicators of hemostasis and fibrinolysis systems in patients with pulmonary tuberculosis and chronic viral hepatitis who underwent COVID-19

    by R.YU. Abdullaev, O.G. Komissarova, V.A. Shorokhova, T.V. Kurmaeva

    Показатели систем гемостаза и фибринолиза у больных туберкулезом легких и хроническими вирусными гепатитами, перенесших COVID-19

  • Open Access

    Parameters of Complete Blood Count and Blood Chemistry during Treatment of Patients with MDR/XDR Pulmonary Tuberculosis with a Short-Course Regimen Containing Bedaquiline, Pretomanid, and Linezolid

    by R. Yu. Abdullaev, A. M. Tikhonov, V. A. Shorokhova, O. G. Komissarova

    The objective: assessment of changes in the parameters of complete blood count, clinical urine tests, and blood chemistry during chemotherapy of patients with MDR/XDR pulmonary tuberculosis receiving the short-course regimen containing bedaquiline, pretomanid, and linezolid (B-Pa-L).Subjects and Methods. 18 patients with MDR/pre-XDR/XDR pulmonary tuberculosis were enrolled into the study. They all received treatment at Central Tuberculosis Research Institute from 2015 to 2022.Results. In the course of chemotherapy of these patients, changes in laboratory test results were noted at different times. Abnormal changes in complete blood count were detected in 10/18 (55,6%) patients during chemotherapy for the 1st time. Hemoglobin levels, erythrocyte and leukocyte counts decreased. Hematuria and bacteriuria were detected by clinical urine test. Proteinuria was observed in almost in half of the patients. Elevated serum potassium level was frequently noted. Blood chemistry demonstrated elevated levels of ALT and AST, which is typical of cytolytic effect on hepatocytes of drugs within chemotherapy. In most cases, all above abnormalities were degree 1 of toxicity and resolved within 2-4 weeks after they were detected. Abnormalities in grade 2-3 of toxicity were mainly observed in patients receiving linezolid at the dose of 1200 mg/day. In most cases, the above abnormalities were detected during the first 4 weeks of chemotherapy.